Table 5 Multivariable analysis: competing risk regression for LC, Cox regression for lung PFS and OS (distant PFS . Hazard ratio and p-value are reported only for the variables included in the multivariable analysis
From: Stereotactic robotic body radiotherapy for patients with oligorecurrent pulmonary metastases
Endpoint | Local control | Lung PFS | Overall survival | |||
|---|---|---|---|---|---|---|
Variables | Hazard ratio (95% CI) | p value | Hazard ratio (95% CI) | p value | Hazard ratio (95% CI) | p value |
Primary histology (adeno vs other) | 0.75 (0.28–2.02) | 0.57 | 0.54 (0.28–1.07) | 0.078 | 0.57 (0.22–1.50) | 0.25 |
Primary tumor site (reference: Lung) | Â | |||||
GI vs Lung | 0.55 (0.14–2.09) | 0.38 | 0.90 (0.43–1.88) | 0.77 | 0.29 (0.08–1.02) | 0.05 |
Other vs Lung | 1.00 (0.39–2.53) | 0.99 | 0.61 (0.27–1.38) | 0.24 | 0.37 (0.11–1.31) | 0.12 |
Prior chemotherapy (yes vs no) | 3.01 (0.76–11.92) | 0.12 | / | / | / | / |
Age > 65 (yes vs no) | 0.64 (0.24–1.67) | 0.36 | / | / | / | / |
Performance status(1+ vs 0) | 4.00 (0.86–18.64) | 0.077 | / | / | 2.46 (0.56–10.74) | 0.23 |
Gender (male vs female) | 2.17 (0.86–5.44) | 0.10 | / | / | / | / |
GTV volume (> 10 cc vs < 10 cc) | 1.92 (0.78–4.75) | 0.16 | / | / | / | / |
BED prescription (> 120 Gy vs < 120 Gy) | 0.35 (0.14–0.87) | 0.025 | / | / | / | / |